Bridgeway Capital Management’s Taysha Gene Therapies TSHA Stock Holding History

Bridgeway Capital Management’s Portfolio TSHA Stock Details TSHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-156,300	Closed	-$494K	–	1418
2023 Q3	$494K	Hold	156,300	–	–	0.01%	873
2023 Q2	$103K	Hold	156,300	–	–	﹤0.01%	1250
2023 Q1	$125K	Buy	156,300 +51,431	+49%	+$66.4K	﹤0.01%	1197
2022 Q4	$237K	Sell	104,869 -35,000	-25%	-$70.9K	0.01%	1048
2022 Q3	$270K	Buy	139,869 +69,060	+98%	+$251K	0.01%	1071
2022 Q2	$263K	Buy	+70,809	New	+$281K	0.01%	1031

Other funds holding TSHA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

TCM

Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Bridgeway Capital Management's TSHA Position: Q4 2023 in Review

Bridgeway Capital Management sold out of Taysha Gene Therapies (TSHA) in Q4 2023, closing a stake of 156,300 shares — an estimated $494K sold.

Bridgeway Capital Management first reported a position in TSHA in Q2 2022 and held it in 6 quarters. The position peaked at $494K in Q3 2023. 87 funds tracked by Wall St. Rank hold TSHA as of Q4 2023.

Bridgeway Capital Management reported no remaining Taysha Gene Therapies position as of Q4 2023 after selling out during the quarter.
Bridgeway Capital Management sold 156,300 Taysha Gene Therapies shares in Q4 2023, an estimated $494K.
Bridgeway Capital Management first reported a position in Taysha Gene Therapies in Q2 2022 and held it in 6 quarters.
Bridgeway Capital Management's Taysha Gene Therapies position peaked at $494K in Q3 2023.
87 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q4 2023.

Based on Bridgeway Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.